DE59811910D1 - Flüssige Interferon-Beta Formulierungen - Google Patents

Flüssige Interferon-Beta Formulierungen

Info

Publication number
DE59811910D1
DE59811910D1 DE59811910T DE59811910T DE59811910D1 DE 59811910 D1 DE59811910 D1 DE 59811910D1 DE 59811910 T DE59811910 T DE 59811910T DE 59811910 T DE59811910 T DE 59811910T DE 59811910 D1 DE59811910 D1 DE 59811910D1
Authority
DE
Germany
Prior art keywords
buffered
interferon beta
hsa
contain
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59811910T
Other languages
German (de)
English (en)
Inventor
Michael Tschoepe
Thomas Siklosi
Peter Schroeder
Hans Hofer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rentschler Biotechnologie GmbH
Original Assignee
Rentschler Biotechnologie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE59811910(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rentschler Biotechnologie GmbH filed Critical Rentschler Biotechnologie GmbH
Application granted granted Critical
Publication of DE59811910D1 publication Critical patent/DE59811910D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Gyroscopes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE59811910T 1997-09-23 1998-09-23 Flüssige Interferon-Beta Formulierungen Expired - Lifetime DE59811910D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97116562 1997-09-23

Publications (1)

Publication Number Publication Date
DE59811910D1 true DE59811910D1 (de) 2004-10-07

Family

ID=8227392

Family Applications (2)

Application Number Title Priority Date Filing Date
DE59811910T Expired - Lifetime DE59811910D1 (de) 1997-09-23 1998-09-23 Flüssige Interferon-Beta Formulierungen
DE59805732T Expired - Lifetime DE59805732D1 (de) 1997-09-23 1998-09-23 Flüssige interferon-beta-formulierungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59805732T Expired - Lifetime DE59805732D1 (de) 1997-09-23 1998-09-23 Flüssige interferon-beta-formulierungen

Country Status (13)

Country Link
US (2) US6923956B1 (fr)
EP (3) EP1224940B2 (fr)
JP (1) JP4293497B2 (fr)
KR (2) KR100711990B1 (fr)
AT (2) ATE224726T1 (fr)
AU (1) AU741300B2 (fr)
CA (1) CA2304808C (fr)
DE (2) DE59811910D1 (fr)
DK (1) DK1017413T4 (fr)
ES (2) ES2223017T5 (fr)
IL (3) IL135186A0 (fr)
PT (2) PT1224940E (fr)
WO (1) WO1999015193A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CA2304808C (fr) † 1997-09-23 2011-03-22 Michael Tschope Formulations liquides d'interferon .beta.
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
EP2261250B1 (fr) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. Protéines de fusion d'albumine et GCSF
WO2004007520A2 (fr) * 2002-07-12 2004-01-22 Medarex, Inc. Procedes et compositions visant a prevenir la degradation oxydative de proteines
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2551510C (fr) * 2003-12-23 2013-07-30 Pharmacia Corporation Formulation liquide stable d'hormones de croissance
CN1984673A (zh) 2004-05-17 2007-06-20 阿雷斯贸易股份有限公司 干扰素水凝胶制剂
EA010979B1 (ru) * 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
BRPI0510527A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
KR101191536B1 (ko) * 2004-06-01 2012-10-15 아레스 트레이딩 에스.에이. 안정화된 인터페론 액상 제제
DE602005011321D1 (de) * 2004-11-10 2009-01-08 Novartis Vaccines & Diagnostic Deamidiertes interferon-beta
TW200640492A (en) * 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
EA015901B1 (ru) 2005-08-26 2011-12-30 Арес Трейдинг С.А. Способ получения гликозилированного интерферона бета
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
RS52417B (en) 2007-12-20 2013-02-28 Merck Serono S.A. PEG-INTERFERON-BETA FORMULATIONS
US9119866B2 (en) 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
DE102008060960A1 (de) * 2008-12-06 2010-06-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Optische Füllstandsmessung
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US8506797B2 (en) * 2011-04-10 2013-08-13 Therapeutic Proteins International, LLC Downstream bioprocessing device
US8852435B2 (en) 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014064637A1 (fr) * 2012-10-26 2014-05-01 Lupin Limited Composition pharmaceutique stable d'une protéine hybride tnfr:fc
WO2014078627A1 (fr) * 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Formulations liquides pour des protéines de fusion tnfr:fc
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
ES8302096A1 (es) 1980-04-03 1982-12-16 Biogen Nv Un metodo de producir un polipeptido que muestra una actividad immunologica obiologica de interferon de fibroblasto hu- mano.
EP0070906B1 (fr) 1981-02-04 1986-10-15 Juridical Foundation Japanese Foundation For Cancer Research Gene d'interferon beta humain
EP0082481B2 (fr) † 1981-12-23 1990-09-12 Schering Corporation Compositions stabilisées d'interféron alpha et leur préparation
AU1234383A (en) 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
JPS59181224A (ja) † 1983-03-29 1984-10-15 Sumitomo Chem Co Ltd 安定なインタ−フエロン製剤の製法
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
CA1294215C (fr) 1986-10-27 1992-01-14 Ze'ev Shaked Compositions pharmaceutiques d'interferon beta recombinant et methodes de formulation
EP0284249A1 (fr) 1987-03-13 1988-09-28 Interferon Sciences, Inc. Composition lyophilisée de lymphokine
DE3712564A1 (de) 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
US4895716A (en) † 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
DE68917883T2 (de) * 1988-05-06 1995-02-23 Toray Industries Stabile interferon-beta-zusammensetzung.
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
JPH06247870A (ja) 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP4878664B2 (ja) * 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物
CA2304808C (fr) † 1997-09-23 2011-03-22 Michael Tschope Formulations liquides d'interferon .beta.

Also Published As

Publication number Publication date
KR100826621B1 (ko) 2008-05-02
JP2001517635A (ja) 2001-10-09
ATE224726T1 (de) 2002-10-15
EP1017413A1 (fr) 2000-07-12
EP1224940B1 (fr) 2004-09-01
KR20010015599A (ko) 2001-02-26
EP1224940A1 (fr) 2002-07-24
KR20060088910A (ko) 2006-08-07
IL135186A (en) 2012-12-31
EP1017413B1 (fr) 2002-09-25
ES2181281T3 (es) 2003-02-16
ATE274917T1 (de) 2004-09-15
CA2304808A1 (fr) 1999-04-01
IL135186A0 (en) 2001-05-20
KR100711990B1 (ko) 2007-05-02
ES2223017T5 (es) 2010-10-15
US20050186177A1 (en) 2005-08-25
EP1224940A8 (fr) 2002-11-20
DK1017413T4 (da) 2008-03-25
WO1999015193A1 (fr) 1999-04-01
ES2223017T3 (es) 2005-02-16
US8337826B2 (en) 2012-12-25
ES2181281T5 (es) 2008-04-16
AU741300B2 (en) 2001-11-29
DK1017413T3 (da) 2003-02-03
EP1426058A3 (fr) 2004-07-28
CA2304808C (fr) 2011-03-22
IL211048A (en) 2012-12-31
JP4293497B2 (ja) 2009-07-08
PT1224940E (pt) 2005-01-31
PT1017413E (pt) 2003-02-28
EP1224940B2 (fr) 2010-08-11
DE59805732D1 (de) 2002-10-31
EP1017413B2 (fr) 2007-11-07
EP1426058A2 (fr) 2004-06-09
US6923956B1 (en) 2005-08-02
AU9627698A (en) 1999-04-12

Similar Documents

Publication Publication Date Title
ATE224726T1 (de) Flüssige interferon-beta-formulierungen
ATE106247T1 (de) Formulierung für rekombinantes beta-interferon, verfahren zur gewinnung und stabilisierung des beta-interferons und dessen verwendung.
DE69428040T2 (de) Orale darreichungsform
LV10178A (lv) Fiziologiski saderigu glabajot stabilu cilveka olbaltumvielu preparatu iegusanas panemiens
LU90806I2 (fr) Ovidrelle-choriogonadotropine alfa et ses d-riv-s pharmaceutiquement acceptables
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
ATE196092T1 (de) Wachstumshormon-enthaltendeproteinformulierung
PL319833A1 (en) Compounds and composition for carrying active media
ATE255450T1 (de) Matrix für iontophorese
IL84985A (en) Sialic acid derivatives with an active carbonyl group useful for extending biological half-life of physiological agents and as couplers for affinity chromatography
ES8900018A1 (es) Procedimiento para la fabricacion de derivados aminoalcoholes peptidicos inhibidores de la renina y de las proteasas acidas
Sauder et al. Stimulation of muscle protein degradation by murine and human epidermal cytokines: relationship to thermal injury
BR9815966A (pt) Formulação humano de interferon beta-1a (ifn-beta-1a) recombinante
WO1996005286A3 (fr) Accelerateurs et inhibiteurs de la mort cellulaire
ES2191825T3 (es) Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
IT8820978A0 (it) Composizione erbicida conselettivita' aumentata e processo per la preparazione di entrambi i componenti ingredienti attivi in un solo stadio.
NZ509773A (en) Casein formulations for the delivery of bioactive constituents
IT1233426B (it) Composizioni farmaceutiche per uso orale ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo, e procedimento per prepararle

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings